Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Organogenesis Holdings Inc. before investing.

In this article, we go over a few key elements for understanding Organogenesis Holdings Inc.’s stock price such as:

• Organogenesis Holdings Inc.’s current stock price and volume
• Why Organogenesis Holdings Inc.’s stock price changed recently
• Upgrades and downgrades for ORGO from analysts
• ORGO’s stock price momentum as measured by its relative strength

About Organogenesis Holdings Inc. (ORGO)

Before we jump into Organogenesis Holdings Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Want to learn more about Organogenesis Holdings Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Organogenesis Holdings Inc..

Organogenesis Holdings Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Organogenesis Holdings Inc.’s stock price was $5.180.

Organogenesis Holdings Inc. is down 4.43% from its previous closing price of $5.420.

During the last market session, Organogenesis Holdings Inc.’s stock traded between $5.110 and $5.430. Currently, there are approximately 126.88 million shares outstanding for Organogenesis Holdings Inc..

Organogenesis Holdings Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Organogenesis Holdings Inc. Stock Price History

Organogenesis Holdings Inc.’s (ORGO) price is currently up 21.88% so far this month.

During the month of November, Organogenesis Holdings Inc.’s stock price has reached a high of $7.080 and a low of $3.840.

Over the last year, Organogenesis Holdings Inc. has hit prices as high as $7.077 and as low as $2.610. Year to date, Organogenesis Holdings Inc.’s stock is up 61.88%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Organogenesis Holdings Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded Organogenesis Holdings Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Organogenesis Holdings Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Organogenesis Holdings Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Organogenesis Holdings Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Organogenesis Holdings Inc. (ORGO) by visiting AAII Stock Evaluator.

Relative Price Strength of Organogenesis Holdings Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Organogenesis Holdings Inc. has a weighted four-quarter relative price strength of 11.52%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how Organogenesis Holdings Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Organogenesis Holdings Inc. Stock Price: Bottom Line

As of November 28, 2025, Organogenesis Holdings Inc.’s stock price is $5.180, which is down 4.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Organogenesis Holdings Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.